Think of it as industrialized drug discovery.

We combine artificial intelligence and machine learning with automation and wet lab validation to conduct experimental biology at unprecedented scale — conducting more than 800,000 experiments every week. Our embrace of high-throughput biology and commitment to a target-agnostic approach are generating novel discoveries. With every experiment, our system gets smarter.

Watch the video

We’re using technology to accelerate every step in drug discovery.

We’ve built the world’s largest dataset of biological images, fit for the purpose of machine learning. We’re training our algorithms on this data to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, to discover new, transformative treatments for patients.

“Deep learning has recently proven capable of driving cars, beating the world champion of the game of Go, translating from one language to another and recognizing faces dramatically better than any previous efforts to date. Recursion is taking this success and applying it to millions of high-resolution cellular images, with a high potential to make biological discoveries with a medical impact and breadth never seen before.”

Yoshua Bengio,
Recursion Scientific Advisor

Our investors

The latest news

Articles and Press Releases
stdClass Object ( [limit] => 3 [order_by] => publish_date [order] => desc [post_types] => Array ( [0] => press-article [1] => press-release ) [template] => press_release [filter_by] => [acf_field] => [tax] => Array ( ) [acf] => )
03.20.20
Dr. Robert Hershberg Joins Recursion’s Board of Directors
Former Chief Scientific Officer and EVP of Business Development at Celgene to bring biopharma experience to digital biology company with multiple clinical-stage assets
03.17.20
Recursion Appoints Dr. Shafique Virani as Chief Corporate Development Officer
Former CEO of Navire Pharma and CoA Therapeutics to lead digital biology company’s pharmaceutical business and clinical development, including its newly formed Development Corporation
01.31.20
Silicon Slopes: Chris Gibson, Co-Founder & CEO, Recursion
Nasdaq chats with Chris Gibson, PhD, Co-Founder & CEO of Recursion, at Silicon Slopes.
Blog and Publications
stdClass Object ( [limit] => 3 [order_by] => publish_date [order] => desc [post_types] => Array ( [0] => post ) [template] => blog [filter_by] => [acf_field] => [tax] => Array ( ) [acf] => )
The Bio-ML Revolution: Who Will Be Drug Discovery’s Next Big Player?
by Lina Nilsson
Data Science
Inclusion: Let’s Keep Learning Together
by Heather Kirkby
Business & Administration
Presidential reflections… before another big year
by Tina Larson
Business & Administration